K. Haider

发表

MRP and MDR1 gene expression in primary breast carcinomas.

G. Dekan, R. Pirker, M. Filipits, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

pS2 protein status fails to be an independent prognostic factor in an average breast cancer population.

H. Heinzl, R. Jakesz, P. Sevelda, 1994, Anticancer research.

Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group.

R. Greil, M. Gnant, H. Samonigg, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer.

W. Scheithauer, W. Kwasny, M. Raderer, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effective second line chemotherapy of advanced breast cancer with navelbine and mitomycin C

W. Scheithauer, R. Pirker, W. Kwasny, 2004, Breast Cancer Research and Treatment.

MDR1 gene expression and its clinical relevance in primary gastric carcinomas

R. Pirker, A. Gsur, M. Götzl, 1993, Cancer.

MDR1 RNA transcripts do not indicate long-term prognosis in colorectal carcinomas.

R. Pirker, K. Haider, D. Depisch, 1997, European journal of cancer.

Expression of the multidrug resistance-associated protein (MRP) gene in colorectal carcinomas.

G. Dekan, R. Pirker, R. Suchomel, 1997, British Journal of Cancer.

Gemcitabine for the Treatment of Advanced Biliary Tract Carcinomas: Evaluation of Two Different Dose Regimens

W. Scheithauer, B. Schneeweiss, W. Kwasny, 1999, Oncology Research and Treatment.

MDR1 gene expression and prognostic factors in primary breast carcinomas.

R. Pirker, J. Spona, K. Haider, 1991, European journal of cancer.

for treatment of advanced

W. Scheithauer, H. Samonigg, H. Hausmaninger, 1990 .

Effective treatment of advanced breast cancer with vinorelbine, 5-fluorouracil and l-leucovorin plus human granulocyte colony-stimulating factor.

W. Scheithauer, W. Kwasny, M. Raderer, 1998, British Journal of Cancer.

Randomised Trial: One Cycle of Anthracycline-Containing Adjuvant Chemotherapy Compared with Six Cycles of CMF Treatment in Node-Positive, Hormone Receptor-Negative Breast Cancer Patients

M. Gnant, H. Samonigg, R. Jakesz, 2003, Oncology Research and Treatment.

Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil, leucovorin and cisplatin

W. Scheithauer, W. Kwasny, G. Locker, 1999, British Journal of Cancer.

Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable early breast cancer.

R. Pötter, M. Gnant, R. Jakesz, 2005, International journal of radiation oncology, biology, physics.

Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6.

M. Gnant, H. Samonigg, R. Jakesz, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tamoxi fen Versus Tamoxi fen Plus Aminoglutethimide as Adjuvant Treatment in Postmenopausal

M. Gnant, H. Samonigg, R. Jakesz, 2003 .

Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer--Austrian Breast and Colorectal Cancer Study Group Trial 5.

M. Gnant, H. Samonigg, R. Jakesz, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized trial of low-dose chemotherapy added to tamoxifen in patients with receptor-positive and lymph node-positive breast cancer.

M. Gnant, H. Samonigg, R. Jakesz, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effective treatment of advanced breast cancer with vinorelbine, mitomycin C plus human granulocyte colony-stimulating factor.

W. Scheithauer, B. Schneeweiss, D. Burger, 1996, British Journal of Cancer.

Unresponsiveness of pancreatic adenocarcinoma to antioestrogen therapy.

W. Scheithauer, G. Kornek, K. Haider, 1990, European journal of cancer.

Amonafide as first-line chemotherapy for metastatic breast cancer.

W. Scheithauer, C. Dittrich, G. Kornek, 1994, European journal of cancer.

Treatment of advanced, refractory breast cancer with alternating docetaxel and epirubicin/cyclophosphamide plus human granulocyte colony-stimulating factor

W. Scheithauer, W. Kwasny, G. Kornek, 2000, Breast Cancer Research and Treatment.

Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial.

W. Scheithauer, B. Schneeweiss, K. Schmid, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment of advanced breast cancer with docetaxel and gemcitabine with and without human granulocyte colony-stimulating factor.

W. Scheithauer, W. Kwasny, M. Raderer, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

A phase II trial of biweekly high dose gemcitabine for patients with metastatic pancreatic adenocarcinoma

W. Scheithauer, B. Schneeweiss, W. Kwasny, 2000, Cancer.

Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma

W. Scheithauer, B. Schneeweiss, K. Schmid, 2003, British Journal of Cancer.

Treatment of advanced breast cancer with gemcitabine and vinorelbine plus human granulocyte colony‐stimulating factor

W. Scheithauer, W. Kwasny, G. Kornek, 1999, Breast Cancer Research and Treatment.

Treatment of advanced breast cancer with vinorelbine and docetaxel with or without human granulocyte colony-stimulating factor.

W. Scheithauer, B. Schneeweiss, W. Kwasny, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment o f A dvanced B reast C ancer w ith V inorelbine a nd Docetaxel W ith o r W ithout H uman G ranulocyte Colony-Stimulati ng F actor

W. Scheithauer, B. Schneeweiss, W. Kwasny, 2001 .

Phase II trial of pegylated liposomal doxorubicin (Caelyx™) plus Gemcitabine in chemotherapeutically pretreated patients with advanced breast cancer

W. Scheithauer, W. Kwasny, G. Kornek, 2007, Acta oncologica.

[Therapy studies of the Austrian Breast Cancer Group (ABC)].

H. Samonigg, R. Jakesz, H. Mischinger, 1998, Zentralblatt fur Chirurgie.

Band 22, Heft 4, August 1999

J. Serth, W. Scheithauer, T. Bauknecht, 1999, Oncology Research and Treatment.

Treatment of Advanced Gastric Cancer with Oral Idarubicin, Leucovorin, and Tegafur

W. Scheithauer, W. Kwasny, M. Raderer, 1999, Oncology Research and Treatment.

Phase II study of amonafide in advanced breast cancer

W. Scheithauer, H. Gisslinger, C. Dittrich, 1991, Breast Cancer Research and Treatment.

Oxaliplatin plus raltitrexed in patients with advanced colorectal carcinoma

W. Scheithauer, W. Kwasny, M. Raderer, 2001, Cancer.

R. Greil, M. Gnant, H. Samonigg, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase II study of CPT-11 plus mitomycin C versus oxaliplatin plus mitomycin C in previously treated patients with advanced colorectal cancer (ACC)

W. Scheithauer, W. Kwasny, G. Kornek, 1999 .